WLWenjin Liu

Wenjin Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenjin Liu has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimization of Multiparametric MRI Sequence Combinations for Early Detection of Chronic Kidney Disease

    by Zhenni Liu, Yunan Gong, Zhonglin Liu, Xiaoqing Wu, Zhiqiang Zhou, Daming Shen, Song’AN Shang, Wenjin Liu, Siyuan Lu, Jing Ye

  • Open Access

    Topological disruptions of metabolic brain networks in early-stage chronic kidney disease

    by Anqi Qiu, Siyuan Lu, Nian Shi, Song’AN Shang, Yuting Zhang, Leihong Zhang, Ao Ruan, Tianyu Li, Zhendong Guo, Daming Shen, et al.

    Although previous arterial spin labeling (ASL) studies have characterized cerebral perfusion alterations in chronic kidney disease (CKD), it remains unclea

  • Local C1q/TNF-related protein 1 attenuates kidney inflammation and fibrosis by regulating macrophage activation

    by Fei Wang, Zhe Gong, Nianjia Yang, Gang Zhou, Mengxue Jia, Wenjin Liu, Huaqing Zheng, Guangyu Bi, Ye Feng

    Augmenting renal CTRP1 expression mitigates chronic inflammation and fibrosis by inhibiting pathological macrophage activation. These findings offer a novel mechanism of kidney inflammation and fibrosis. CTRP1 can be considered as a predictive marker and/or therapeutic target for patients with CKD.


  • Heterogeneous Graph-Based Multimodal Brain Network Learning

    by Gen Shi, Yifan Zhu, Wenjin Liu, Quanming Yao, Xuesong Li

    Graph neural networks (GNNs) provide powerful insights into brain neuroimaging technology from the view of graphical networks. However, most existing GNN-based models treat the brain connectome, derived from neuroimaging, as a homogeneous graph characterized by uniform node and edge types. In fact, emerging studies have reported and emphasized the significance of heterogeneity among human brain activities, especially between the two cerebral hemispheres. Thus, homogeneous-structured brain network-based graph methods are insufficient for modeling complicated cerebral activity states. To overcome this problem, we introduce a novel heterogeneous graph neural network (HeBrainGNN) for multimodal brain neuroimaging fusion learning. HeBrainGNN first conceptualizes the brain network as a heterogeneous graph with multiple types of nodes (representing the left and right hemispheres) and edges (categorizing intra- and interhemispheric interactions). We further develop a self-supervised pretraining strategy for this heterogeneous network to address the potential overfitting problem caused by the conflict between a large parameter size and a small medical data sample size. Empirical results show the superiority of the proposed model over other existing methods in brain-related disease prediction tasks. Ablation experiments show that our heterogeneous graph-based model attaches more importance to hemispheric connections that may be neglected due to their low strength by previous homogeneous graph models. Additional experiments reveal that our pretraining strategy not only addresses the challenge of limited labeled data but also significantly enhances accuracy, affirming the potential of our approach in advancing neuroimaging analysis.


  • A novel soluble guanylate cyclase activator, avenciguat, in combination with empagliflozin, protects against renal and hepatic injury in diabetic db/db mice

    by Nisha Sharma, Wenjin Liu, Xiao-Qing E. Tsai, Zhou Wang, Connor Outtrim, Anna Tang, Michael P. Pieper, Glenn A. Reinhart, Yufeng Huang

    Whether combining an sGC activator with an SGLT2 inhibitor could better control diabetes-associated oxidative stress and NO-cGMP signal deficiency has not yet been explored. Using the type 2 diabetic db/db mouse model, this study underscores the sGC activator avenciguat as a novel therapy for diabetic nephropathy and liver injury beyond sGLT2 inhibitors. It also highlights the need for further investigation into the combined effects of these two treatments in managing diabetic complications.


  • Open Access

    Repurposing Niclosamide to Modulate Renal RNA-Binding Protein HuR for the Treatment of Diabetic Nephropathy in db/db Mice

    by Lili Zhuang, Wenjin Liu, Xiao-Qing Tsai, Connor Outtrim, Anna Tang, Zhou Wang, Yufeng Huang

    Hu antigen R (HuR) plays a key role in regulating genes critical to the pathogenesis of diabetic nephropathy (DN). This study investigates the therapeutic potential of niclosamide (NCS) as an HuR inhibitor in DN. Uninephrectomized mice were assigned to four groups: normal control; untreated db/db mice terminated at 14 and 22 weeks, respectively; and db/db mice treated with NCS (20 mg/kg daily via i.p.) from weeks 18 to 22. Increased HuR expression was observed in diabetic kidneys from db/db mice, which was mitigated by NCS treatment. Untreated db/db mice exhibited obesity, progressive hyperglycemia, albuminuria, kidney hypertrophy and glomerular mesangial matrix expansion, increased renal production of fibronectin and a-smooth muscle actin, and decreased glomerular WT-1+-podocytes and nephrin expression. NCS treatment did not affect mouse body weight, but reduced blood glucose and HbA1c levels and halted the DN progression observed in untreated db/db mice. Renal production of inflammatory and oxidative stress markers (NF-κBp65, TNF-a, MCP-1) and urine MDA levels increased during disease progression in db/db mice but were halted by NCS treatment. Additionally, the Wnt1-signaling-pathway downstream factor, Wisp1, was identified as a key downstream mediator of HuR-dependent action and found to be markedly increased in db/db mouse kidneys, which was normalized by NCS treatment. These findings suggest that inhibition of HuR with NCS is therapeutic for DN by improving hyperglycemia, renal inflammation, and oxidative stress. The reduction in renal Wisp1 expression also contributes to its renoprotective effects. This study supports the potential of repurposing HuR inhibitors as a novel therapy for DN.


  • Contrastive Hierarchical Augmentation Learning for Modeling Cognitive and Multimodal Brain Network

    by Gen Shi, Yuxiang Yao, Yifan Zhu, Xinyue Lin, Lanxin Ji, Wenjin Liu, Xuesong Li

    Brain networks generated by functional magnetic resonance imaging (fMRI) have shown promising performance in characterizing cerebral social cognition and disorders. However, the scarcity of labeled data has hindered the application of deep graph learning in brain network analysis, accelerating the usage of extra label-free self-supervised contrastive graph learning. However, existing augmentation strategies commonly used in contrastive learning (CL), such as edge and node drop, do not fully benefit brain network learning due to the distribution differences between different modalities of brain neural imaging. To this end, we introduce a novel approach namely spatial–temporal hierarchical augmentation-based contrastive learning (ST-HACL) to enhance the representation learning of functional brain networks. ST-HACL leverages augmentation methods tailored specifically to brain networks. Our method employs an augmentation strategy from both spatial and temporal level during the brain network construction process to generate contrastive samples, enabling label-free self-supervised learning. We evaluate the performance of our approach on the orthostatic hypotension dataset (OH) and the Alzheimer’s disease neuroimaging initiative dataset (ADNI). Results demonstrate that our model surpasses existing graph neural network (GNN) models and graph-CL methods, achieving F1 scores of 80.61% in OH and 73.01% in ADNI. To the best of our knowledge, our study represents the first attempt at applying brain network-specific contrastive augmentation learning to fMRI analysis.


  • Open Access

    Corrigendum to “Intracranial vascular feature changes in time of flight MR angiography in patients undergoing carotid revascularization surgery” [Magn. Reson. Imaging, 75, Jan 2021, 45–50]

    by Zhensen Chen, Li Chen, Manabu Shirakawa, Wenjin Liu, Dakota Ortega, Jinmei Chen, Niranjan Balu, Theodore Trouard, Thomas S. Hatsukami, Wei Zhou, et al.

  • Open Access

    Heterogeneous Graph-Based Multimodal Brain Network Learning

    by Gen Shi, Yifan Zhu, Wenjin Liu, Quanming Yao, Xuesong Li

    Graph neural networks (GNNs) provide powerful insights for brain neuroimaging technology from the view of graphical networks. However, most existing GNN-based models assume that the neuroimaging-produced brain connectome network is a homogeneous graph with single types of nodes and edges. In fact, emerging studies have reported and emphasized the significance of heterogeneity among human brain activities, especially between the two cerebral hemispheres. Thus, homogeneous-structured brain network-based graph methods are insufficient for modelling complicated cerebral activity states. To overcome this problem, in this paper, we present a heterogeneous graph neural network (HebrainGNN) for multimodal brain neuroimaging fusion learning. We first model the brain network as a heterogeneous graph with multitype nodes (i.e., left and right hemispheric nodes) and multitype edges (i.e., intra- and interhemispheric edges). Then, we propose a self-supervised pretraining strategy based on a heterogeneous brain network to address the potential overfitting problem caused by the conflict between a large parameter size and a small medical data sample size. Our results show the superiority of the proposed model over other existing methods in brain-related disease prediction tasks. Ablation experiments show that our heterogeneous graph-based model attaches more importance to hemispheric connections that may be neglected due to their low strength by previous homogeneous graph models. Other experiments also indicate that our proposed model with a pretraining strategy alleviates the problem of limited labelled data and yields a significant improvement in accuracy.

  • C-X-C Motif Chemokine Ligand 16 Is a Potent Predictor of Outcomes in Dialysis Patients

    by Wenjin Liu, Lulu Wang, Xiurong Li, Chaoqing Gao, Jianmei Zhou, Jiajun Zhou, Liang Wang, Zhuxing Sun, Hong Chu, Wei Fan, et al.

    Introduction: C-X-C motif chemokine ligand 16 (CXCL16) is an inflammatory marker that has been found to be predictive of outcomes in patients with cardiovascular disease. Our previous work has also demonstrated its relation to cardiac injury in dialysis patients. However, it is yet unclear whether there is an association between CXCL16 and adverse outcomes in dialysis patients. We aimed to evaluate its prognostic value along with several traditional inflammatory markers in the current study. Methods: This is a multicenter longitudinal study of prevalent dialysis patients. Circulating inflammatory markers including CXCL16, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 (IL-6) were measured using a multiplex assay. The primary outcomes were all-cause mortality and a composite of major adverse cardiovascular events (MACEs). The associations between biomarkers and outcomes were analyzed using Cox proportional hazards regression models. Results: Of the 366 participants with available plasma samples, the average age was 52.5 (±12.1) years, and there were 160 (43.7%) female participants. For all-cause mortality, logarithmically transformed CXCL16, IL-6, and CRP were independent predictors after adjustment for covariates. When the 3 markers were included in the same model, CXCL16 was the only one remaining its significance. For MACEs, logarithmically transformed CXCL16 and IL-6 were significant predictors when analyzed separately and CXCL16 was an independent predictor even after adjustment for IL-6. When the biomarkers were analyzed as categorical variables, only CXCL16 was associated with both outcomes. Adding CXCL16 to established risk factors improved risk prediction as revealed by Net Reclassification Index (NRI). Conclusion: Using a multimarker approach, we determined that CXCL16 is a potent predictor of all-cause mortality and cardiovascular events in dialysis patients. Our data suggest CXCL16 may improve risk stratification and could be a potential interventional target.